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Pulmonary lymphangioleiomyomatosis (LAM) is a rare interstitial disease of 
uncertain etiology that almost exclusively occurs in women, most often of 
childbearing age. LAM is characterized by proliferation in the bronchioli, pul-
monary veins and lymphatic vessels of cysts lined by atypical smooth muscle 
cells (LAM cells) [1][2]. Progressive occlusion of these structures most often 
leads to serious clinical manifestations including worsening dyspnea, often 
accompanied by cough, chest pain, hemoptysis, pneumothorax and chylotho-
rax. Pneumothorax results from cystic rupture, chylothorax results from ob-
struction of pulmonary lymphatics and hilar lymph nodes by the slowly prolif-
erating LAM cells. Pulmonary function abnormalities in LAM consist of gas 
exchange abnormalities, characterized by a decreased diffusion capacity of 
the lung for carbon monoxide (DLCO) and airflow obstruction. In many pa-
tients, progressive lung damage occurs and functional impairment is severe, 
leading to incapacitation and complete disability, requiring long-term oxygen 
therapy and lung transplantation, or causing death. The rate of progression of 
disease, however, is variable, and some patients have a long- term course 
lasting >20 years [3][4].     
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Prevalence of LAM 
LAM occurs sporadically in patients with no evidence of genetic disease and 
in about one third of women with Tuberous Sclerosis complex (TSC) [5][6][7], 
an autosomal dominant syndrome characterized by hamartoma-like tumor 
growths in various organs, cerebral calcifications, seizures, and mental retar-
dation that occurs in 1 of 5,800 live births [8]. 
Based on the prevalence of TSC, it is estimated that there may be as many 
as 7,500 TSC patients with LAM in the United States. 
Sporadic LAM, however, which is not associated with a TSC phenotype, is a 
relatively uncommon disease with a prevalence that has been estimated at 2 
to 6 per million women [9]. 
Our group of patients represents one of the largest series with sporadic LAM 
ever reported in Italy (75 patients at writing). We described the first case of 
definite diagnosis of LAM in a karyotypically normal man without TSC [10]. 
 
 
Diagnosis of LAM 
The diagnosis of LAM should be considered in a woman of any age who pre-
sents with recurrent pneumothorax, chylous pleural effusions, and/or ascites, 
or an unexplained decrease in exercise tolerance. The single most important 
diagnostic test is a CT scan of the thorax, with high resolution views to facili-
tate visualization of the cysts. In patients  with TSC, the identification of lung 
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cysts on the CT scan strongly suggests the diagnosis of LAM. The coexis-
tence of angiomyolipomas (AMLs) and lung cysts is also virtually diagnostic 
of LAM. On the other side patients presenting with apparent sporadic LAM 
may have TSC. As TSC has a highly variable phenotype and two thirds of 
cases arise as spontaneous mutations the diagnosis can be overlooked. Pa-
tients should undergo a full history and physical examination to exclude TSC. 
Physical examination should include the skin, retina and nervous system by a 
physician familiar with the manifestations of TSC [11]. (Fig.1) As TSC com-
prises manifestations in multiple organ systems, full evaluation for TSC may 
require more than one specialist.   Table 1-2 
 
Major feature Minor features 
Facial angiofibromas or forehead 
plaque  
Multiple randomly distributed pits in 
dental enamel  
Non-traumatic ungual or periungual 
fibroma  
Hamartomatous rectal polypsc  
Hypomelanotic macules (more than 
three)  
Bone cystsd  
Shagreen patch (connective tissue 
nevus)  
Cerebral white matter migration 
lines a,d,e  
Multiple retinal nodular hamarto-
mas  
Gingival fibromas  
Cortical tubera  Non-renal hamartomac  
Subependymal nodule  Retinal achromic patch  
Subependymal giant cell astro-
cytoma  
"Confetti" skin lesions  
Cardiac rhabdomyoma, single or 
multiple  
Multiple renal cystsc  
Pulmonary lymphangioleiomyoma-
tosis or renal angiomyolipomab  
 
Table 1. Revised Diagnostic Criteria for Tuberous Sclerosis Complex [11]  
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Definite TSC: either 2 major features or 1 major feature and 2 minor features.  
Probable TSC: one major feature and one minor feature.  
Possible TSC: either 1 major feature or 2 or more minor features.  
(a) Co-existent cerebral cortical dysplasia and cerebral white matter migration 
tracts count as one feature. (b) Co-existent LAM and renal angiomyolipomas 
count as one feature. (c) Histologic confirmation suggested. (d) Radiographic 
diagnosis sufficient.  
 
 
Assessment Timing / repeat testing 
Neurodevelopmental testing At diagnosis / as indicated 
Ophthalmic examination At diagnosis / as indicated 
Electroencephalography If seizures occur / as indicated 
Echocardiography If symptoms occur / as indicated 
Renal ultrasonography At diagnosis / every 1-3 years 
Cranial CT / MRI At diagnosis / children adolescents 
1-3 years or as indicated 
Table 2. Recommended assessment of new patients with TSC.  
TSC Consensus Conference 1998.  
 
             
    
Fig.1   Neurological and cutaneous manifestation of TSC 
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Lung cysts are the hallmark lesion in LAM and are present in all patients 
[12][13]. Their appearance, size and contour vary considerably typically rang-
ing from 2-5mm in diameter but occasionally as large as 30mm [14]. Cysts 
are usually round, distributed evenly throughout the lungs with normal lung 
parenchyma. Cysts wall thickness ranges from barely perceptible to 2mm in 
most series but has been described as measuring up to 4mm [14]. (Fig 2 a-b) 
 
 
 
Fig.2a  Chest radiography of a patient with LAM 
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Fig.2b  High resolution axial CT image of the chest of a patient 
with LAM. Note diffuse involvement of the lung parenchyma, with 
numerous thin-walled cysts. 
 
The presence of lung cysts on a CT scan with no evidence of TSC, AMLs, 
lymphangioleiomyoma or chylothorax is not diagnostic of LAM. Other un-
common diseases presenting with lung cysts, such as Birt-Hogg-Dubé syn-
drome, Langerhans cell histiocytosis, and Sjögren’s syndrome, should be 
considered. Under these circumstances, a lung biopsy is recommended [15].  
Abdominal CT scanning can be used to detect angiomyolipomas, lymphan-
gioleiomyomas or lymphadenopathy to support the diagnosis, to plan the 
management of angiomyolipomas, and to follow their evolution. Abnormal 
abdominopelvic imaging findings in patients with LAM are found in up to two 
thirds of patients [16]. CT is more sensitive and specific than ultrasound and 
can detect tumour <1cm in diameter [16]. Magnetic resonance imaging (MRI) 
with and without fat suppression techniques may be adequate for the diag-
nosis of fat-containing tumours when iodinated contrast is contraindicated.  
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Gross specimens from open lung biopsies or autopsies contain cysts 
throughout the lung parenchyma that are 0,5 to 2,0 cm in size [17]. (Fig.3) 
             
                    
        Fig.3   Gross pathology of lung in a patient with severe LAM.   
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On microscopic examination, discrete foci of abnormal smooth muscle cells 
abut cystic structures lined with hyperplastic type II pneumocytes. The foci 
contain centrally located, small, spindle-shaped cells with larger epithelioid 
cells at the periphery, all of which are arranged in haphazard fashion. In ad-
dition to LAM cell foci, patients with TSC may also exhibit MMPH, a feature 
characterized by ill-defined nodules consisting of alveoli with hyperplastic 
type II pneumocytes. 
Consistent with their classification as smooth muscle cells, LAM cells react 
with several smooth muscle-specific antibodies and with HMB-45, a mono-
clonal antibody that reacts with gp100, a melanocyte antigen found in 
premelanosomes. In support of a role for sex hormones in the pathogenesis 
of LAM, epithelioid LAM cells reacted strongly with antibodies to estrogen 
and progesterone receptors [17]. (Fig.4) 
Herein, special immunofluorescent stains for smooth muscle α-actin, 
vimentin, desmin, and HMB45 should be performed especially where mor-
fologic features do not allow a secure diagnosis to be made. The estrogen 
and progesterone receptor may be an adjunct to diagnosis [11]. 
Like the radiological pattern, the histological one is also characteristic in 
LAM, so that transbronchial or surgical lung biopsy and histological studies, 
integrated with immunohistochemistry, have to be used to confirm the diag-
nosis. The use of immunohistochemical staining with HMB45, the hallmark of 
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diagnosis, has improved the usefulness of transbronchial biopsy in the diag-
nosis of LAM. (Fig.5)            
 
 
                                                                                                                           
        
 
  Fig.4  Histological pattern of LAM. From reference 41 
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Fig.5  a)Normal lung, low power             b)LAM, low power 
 
 
   
c)LAM, high power                                 d)LAM, HMB-45 stain 
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Although most AMLs occur in the absence of LAM (Fig.6), the accidental find-
ing of a kidney mass by abdominal sonogram or CT scan suggesting the 
presence of an AML mandates a CT scan of the lungs to look for lung 
cysts[15]. 
 
     
Fig.6 Renal angiomyolipomas in LAM patients 
 
 
Extrapulmonary LAM can be observed in 3 major locations: the posterior me-
diastinum, the upper retroperitoneal areas close to the abdominal aorta, and 
the pelvic cavity. These predominant locations of LAM are related to the 
anatomic distribution of lymphatic vessels; the morphologic and immunohis-
tochemical heterogeneity of LAMcells in extrapulmonary LAM is similar to that 
in pulmonary LAM [18].  
Matsui described the lesions of lymphangioleiomyomatatosis in patients with 
masses occurred in the mediastinum, in the retroperitoneum and in the pelvis; 
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sometimes the diagnosis of pulmonary LAM was established after that of ex-
trapulmonary LAM.  
We recently described a young woman presenting with chyluria secondary to 
the presence of a large retroperitoneal lymphangioleiomyoma [19]. (Fig.7) 
 
 
 
 
Fig.7 Multi-slice spiral CT, coronal reformatted image showing a retroperito-
neal mass located in close proximity with the thoracic duct. 
From reference 19                 
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Fig.8 From reference 11 
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Treatment 
As soon as the diagnosis is established, therapy should be initiated, because 
of its progressive nature. LAM is a rare disease and it explains the lack of 
data from controlled trials focusing on treatment. Estrogens have been impli-
cated in the pathogenesis of LAM based on a number of convincing evi-
dence, including the identification of ERs in the context of LAM cells 
[20][21][22], and the occurrence of the disease primarily in women of child-
bearing age. 
There are numerous reports of patients being treated with oophorectomy 
[23][24][25][26], progesterone [24][25], tamoxifen or other antiestrogen 
agents[23][24][27], gonadodropin-releasing hormone analogue[28][29][30], 
or radioablation of the ovaries. In many reports, various combinations of 
these treatments have been attempted, and responses to such treatments 
have been variable. The choice between the different approaches is largely 
dictated by the specific experience of the different Authors.   
More recently, patients with end-stage lung disease related to LAM have 
been treated with lung transplantation [31][32][33]; some reports document 
LAM recurrence after single-lung transplantation [34][35][36], raising the 
possibility of some type of circulating mitogen in the pathogenesis of the dis-
ease. 
Lung transplant shouldn’t be regarded as the first choice treatment of LAM, 
but the extreme measure only in patients in end-stage disease.  
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The use of tamoxifen as antiestrogenic therapy was first described in 1982 
[37] and since then it has been used, with varying results, in different stud-
ies. In some cases it led to a worsening of the symptoms [38]. The weak par-
tial estrogen-agonist activity that tamoxifen is known to have might have 
caused the stimulation of estrogens receptors in those cases. Moreover, in 
some models tamoxifen acts as an estrogens antagonist, but may not pro-
duce the expected results because acting on atypical receptors of LAM mus-
cular tissue. Because of these contradicting data tamoxifen is now not rec-
ommended in the treatment of LAM.   
Medroxyprogesterone acetate is used because of its effect as an estrogens 
antagonist; however, a higher incidence of meningiomas in patients treated 
with this drug compared to the general population has been recently re-
ported [39], and this observation has raised some concerns about the use of 
this medication. A case of symptomatic meningioma requiring surgical exci-
sion also occurred in one of our patients [40].  
As an alternative to medroxyprogesterone it is possible to use letrozole, a 
pharmacological inhibitor of the enzyme aromatase, in order to inhibit the es-
trogenic activity in LAM patients.  
We suggest a therapeutic opportunity through sex hormonal manipulation: 
discontinuation of preparations containing estrogens, avoiding pregnancy, 
eradication of estrogenic activity and induction of menopause. Our data by 
women with LAM, collected over a period of more than 20 years, led us to the 
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assumption that hormonal factors play an important role in the pathogenesis 
of the disease [41]. In fact the timely administration of estrogen suppression 
allows a dramatic improvement in the prognosis of these patients, leading to 
higher survival rates than studies appeared before hormonal treatment was 
introduced. These clinical findings are supported by in vitro and in vivo data 
about LAM pathogenesis [22][42]. 
However, other studies showed that hormonal modulation (using a number of 
different approaches) failed to provide consistent, reproducible proofs of effi-
cacy [37][43][44][45]. In this regard, a recent report suggested limited efficacy 
of triptoreline therapy [46]. However, in this study on 11 patients (9 of which 
had pathologic confirmation of their disease) no data were reported about the 
expression of estrogen receptors and HMB-45. 
LAM is associated with inappropriate activation of mammalian target of rapa-
micin (mTOR) signaling, which regulates cellular growth and lymphangio-
genesis. Sirolimus (also called rapamicin) inhibits mTOR. (Fig.9) 
A report including both patients with TSC and sporadic LAM showed that si-
rolimus monotherapy reduced angiomyolipoma volume of nearly 50%. Con-
versely, improvements in airflow and gas trapping were limited to patients 
with LAM [47]. However, the rate of adverse effects was high, and only a 
small number of patients had renal and pulmonary benefits that persisted af-
ter the drug was stopped. Another recent report [48] shows that treatment 
with sirolimus for 1 year has beneficial effects in patients with LAM, including 
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the stabilization of FEV1 and improvement in FVC, quality of life, and some 
functional performance measures. But sirolimus therapy positively affected 
lung function only during the treatment period and it was associated with a 
large number of different adverse events.   
 
Fig.9 The mTOR pathway is constitutively activated in LAM.  
From reference 47 
 18
Recently the European Respiratory Society (ERS) guidelines for the diagno-
sis and management of LAM recommended that hormone treatments should 
not be used in patients with LAM (Grade: Inconclusive, Quality: low, Benefit: 
conflicting, Consensus: very good) [11]. On the other side, ERS guidelines 
also recommended that sirolimus should not be prescribed routinely outside 
clinical trials and that in renal angiomyolipoma mTOR inhibitors should not be 
used as first-line therapy (Grade: C, Quality: low, Benefit: small/weak, Con-
sensus: very good) [11]. 
As LAM is rare, there have been no controlled trials of its management. 
Therefore, despite recent somewhat promising results, effective treatment for 
patients with LAM is still lacking and ERS guidelines for LAM don’t produce 
conclusive indications about effective therapeutic strategies.   
 
 
Management 
In common with other pulmonary diseases, patients with LAM should be en-
couraged to maintain a normal weight and refrain from smoking. The diagno-
sis of an orphan disease and its consequences often leave patients with a 
feeling of isolation. Patient groups can help with these issues and other prac-
tical matters.   Patients with both sporadic and TSC-LAM including those with 
no or minimal symptoms must be warned of the risk of pneumothorax and 
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told to seek urgent medical attention in the event of symptoms of pneumotho-
rax.
Indeed LAM is associated with an increased risk of pneumothorax which oc-
curs in ~40% of patients at presentation and 66% of patients during the 
course of the disease. The estimated rate of recurrence after the first episode 
in LAM is ~75% [11].  
It is likely that pregnancy in LAM is associated with an increased risk of 
pneumothorax and chylothorax. It is suspected that pregnancy may acceler-
ate the decline in lung function. It is likely that patients with poor baseline lung 
function are less likely to tolerate a pneumothorax or chylous effusion during 
pregnancy. There may be an increased risk of bleeding from angiomyolipoma 
during pregnancy [11].  
Anyway to become pregnant is the patients' decision. However all patients, 
including those with few or no symptoms, should be informed that there is a 
greater risk of pneumothorax and chylous effusion during pregnancy. Those 
with recurrent pneumothorax or effusion outside pregnancy and those with 
poor baseline lung function are at greater risk during pregnancy. It may be 
appropriate to discourage patients with severe disease from becoming preg-
nant.
Exogenous oestrogens may promote the progression of pulmonary LAM in at 
least some cases [11] therefore females with LAM should avoid oestrogen 
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containing treatments including the combined oral contraceptive pill and hor-
mone replacement therapy. 
Reports of pneumothorax occurring in flight have resulted in females with 
LAM being advised not to travel by air. Patients with sporadic and TSC-LAM 
with well preserved lung function do not need to take specific precautions or 
avoid air travel. Those with advanced disease should be evaluated for the 
need for oxygen during flight to prevent hypoxaemia and as they are less 
likely to tolerate pneumothorax.  
Patients with a known untreated pneumothorax, or a pneumothorax treated 
within the previous month, should not travel by air. 
LAM is associated with reduced bone mineral density in a significant propor-
tion of patients. Patients with LAM, especially those post-menopause, should 
undergo periodic evaluation of bone mineral density. Those with osteoporosis 
should be treated the same as other patients with osteoporosis. In view of the 
rapid deterioration in bone mineral density observed after lung transplanta-
tion, aggressive therapy for osteoporosis should be initiated early in LAM pa-
tients with severe lung disease and osteopenia at any bone site. In addition to 
pharmacological therapy, weight-bearing exercise and strength training 
should be encouraged [11]. 
One quarter of patients respond to inhaled bronchodilators according to stan-
dard objective criteria and more may obtain some clinical benefit. Patients 
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who respond to bronchodilators tend to have airflow obstruction and have a 
greater rate of decline in FEV1. Although bronchiolar inflammation is seen in 
some patients the efficacy of inhaled corticosteroids in LAM has not been as-
sessed.  
 
Complications and co-morbidities
Pneumothorax occurs in the majority of patients, results in significant hospital 
stays, and is frequently recurrent. Conservative treatments are associated 
with higher rates of recurrence than pleurodesis via chest tube or appropriate 
surgical interventions. Lung transplantation in patients with previous thoracic 
surgery or pleural procedures may be associated with increased technical dif-
ficulty and an increased risk or perioperative bleeding.  
Chylothorax in LAM may be almost asymptomatic or cause marked dysp-
noea. The interventions used for the management of chylothorax in LAM 
should be appropriate for the size and clinical impact of the effusion, comor-
bid factors and local expertise. A fat-free diet (with or without oral supplemen-
tation of medium-sized triglycerides) or fat-free total parenteral nutrition has 
been used occasionally to minimise the volume of chyle formation. For small 
effusions, observation or thoracocentesis may be sufficient [11].  
Finally patients should be advised to seek urgent medical attention in the 
presence of symptoms of bleeding angiomyolipoma.  
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Although experience is based on data from case series, both embolisation 
and nephron sparing surgery have been performed safely without compromis-
ing renal function both in elective cases and acute renal haemorrhage, includ-
ing during pregnancy. Embolisation can be performed for active bleeding, is 
less invasive and does not require general anaesthesia but may need to be 
repeated. Embolisation may be favoured over surgery in patients with bleed-
ing angiomyolipoma, although no trials have compared the two strategies. 
The intervention used depends upon technical factors associated with the 
tumour and local expertise. When bleeding is not present, nephron sparing 
surgery may be preferred when a malignant lesion is suspected. Surgery with 
intra-operative frozen section biopsy may be considered with the option to 
perform conservative or radical surgery; the risk of a false diagnosis of carci-
noma must be borne in mind [11]. Decisions are best made electively after 
screening for angiomyolipoma or in response to symptoms rather than in the 
setting of an acute haemorrhage, early detection of angiomyolipoma is there-
fore important. The risk of bleeding is linked to angiomyolipoma size and is 
clinically appreciable in tumours ≥4 cm in diameter and where aneurysms are 
≥5 mm. Therefore asymptomatic renal angiomyolipoma <4 cm should not be 
treated, but should be followed by yearly ultrasound unless symptoms occur. 
Renal angiomyolipomas >4 cm or with renal aneurysms >5 mm in diameter 
are at an increased risk of bleeding, and should be followed by ultrasound 
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imaging twice yearly to evaluate growth. Treatment by embolisation or 
nephron sparing surgery should be considered.  
LAM accounts for 1.1% of lung transplant recipients [49]. LAM compares fa-
vourably to patients transplanted for other indications [31]. In a recent survey 
the actuarial survival of lung transplantation for LAM was 86% at 1 yr, 76% at 
3 yrs, and 65% at 5 yrs [50].  
Due to the small number of patients treated and variable rates of decrease in 
lung function, firm recommendations are difficult to make. In a recent survey 
of patients undergoing transplantation for LAM, most had severe airway ob-
struction and were transplanted with a mean FEV1 of  ~25% and DL,CO of 
27% predicted [50]. Patients should be considered for lung transplantation 
when they reach New York Heart Association (NYHA) functional class III or IV 
with severe impairment in lung function and exercise capacity (V′O2,max 
<50% pred, hypoxaemia at rest). Transplantation in patients >65 yrs of age 
may only be considered exceptionally.  
Both single, and more commonly, bilateral lung transplantations have been 
performed for LAM. Although a bilateral lung transplant is associated with bet-
ter post-transplant lung function and a reduction in LAM-related complications 
there is no difference in survival between the two procedures[50]. Therefore 
the choice of a single, or bilateral lung transplant in LAM should be deter-
mined by surgical technical factors and organ availability.  
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Patients with TSC have received successful lung transplantation for severe 
LAM [51][52]. Although no TSC specific problems have been identified, pa-
tients with TSC-LAM are likely to have more comorbidities than those with 
sporadic LAM. The impact of these processes and their treatment require 
careful pre-transplant evaluation.  
 
Prognosis and Natural history 
Predicting the prognosis of individual patients is difficult. Histological extent 
of disease and some lung function variables have been found to be predic-
tive at diagnosis, of either survival or more rapid deterioration of lung func-
tion. LAM is less severe in TSC-LAM than sporadic LAM although this may 
reflect ascertainment bias. None of these predictors have been validated 
prospectively and moreover, some of these variables may only reflect more 
advanced disease at the time of diagnosis resulting in shorter survival. 
DLCO and FEV1 are likely to be the best current indicators of disease pro-
gression and survival. Patients with TSC-LAM may have a more indolent 
course than those with sporadic LAM. 
Forced expiratory volume in 1s (FEV1) and transfer factor of the lung for car-
bone monoxide (DLCO) correlate with CT and histological abnormalities in 
LAM and change over time as the disease progresses. DLCO, abnormal in 
more patients than FEV1, may be a more sensitive indicator of early disease. 
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Spirometry, bronchodilator testing and DLCO should be performed in the ini-
tial evaluation of patients with LAM (including TSC-LAM); then FEV 1 and 
DLCO should be performed to assess disease progression and response to 
treatment. Lung function tests should be repeated every 3-6 months in patient 
with progressive disease and every 6-12 months in those with more stable 
disease, as determined by a period of observation of 1year [11]. 
The natural history of the disease has been dramatically changed by hormo-
nal treatment. Up to the 80s the survival rate was 20% at 10 years from the 
time of the onset, while in more recent studies the survival has risen to 70% 
at 10 years and 71% at 15 years [49]]53][54]. 
In our group of patients the survival was 97% at 5 years, 90% at 10 years 
and 71% at 25 years [41]. 
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STUDY 
 
 
 
 
INTRODUCTION 
Lymphangioleiomyomatosis (LAM) is a rare progressive cystic lung disease 
of uncertain etiology that affects young women. The most common clinical 
manifestation is the insidious onset of exertional dyspnoea; patients may also 
experience a non productive cough. Other common features include sponta-
neous pneumothorax, which results from cystic rupture, and chylothorax, 
which results from obstruction of pulmonary lymphatics and hilar lymph nodes 
by the slowly proliferating LAM cells. Less frequently, haemoptysis or chylop-
tysis may occur [55]. Death usually occurs from respiratory failure and it is a 
common opinion that there is no proven treatment. 
LAM is a destructive, eventually fatal lung disease, which affects women of 
childbearing age at the time of diagnosis [56][57]. Pregnancy and use of oral 
contraception are associated with a higher frequency of exacerbations and a 
more aggressive disease course [58][59][60]. LAM can also be found in post 
menopausal women taking hormone replacement therapy. In support of a role 
of sex hormones in the pathogenesis of LAM biochemical and immunohisto-
chemical techniques revealed expression of estrogen receptors (ER) and 
progesterone receptors in cells of LAM lesions [61].  Based on these clinical 
and biochemical findings, estrogens were hypothesized to invoke or, at least, 
contribute in a principal manner to the progression of LAM. 
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Treatments for LAM have consisted mostly of oophorectomy and hormonal 
manipulations with progesterone or other agents. The efficacy of gonadotro-
phin-releasing hormone (Gn-RH) agonists and analogues in the treatment of 
LAM has also been the subject of several reports with conflicting results [41] 
[55]. Harari et al, in a prospective analysis of lung function decline in 11 pa-
tients with LAM, found that treatment with triptorelin did not affect disease 
progression [61]. 
We analysed the lung function in 21 patients with LAM treated with estrogen 
suppression obtained with oophorectomy alone, triptorelin alone, or triptorelin 
followed by oophorectomy. 
 
METHODS 
We reported the analysis of the response to estrogen suppression in 21 LAM 
patients. 
To quantify the lung function, we selected FEV1, FVC and DLCO, because 
these tests correlate well with disease severity defined by CT-scans and LAM 
histology scores; they also reflects the airway and alveolar involvement by 
Lymphangioleiomyomatosis. We also examined gas exchange at rest. 
We evaluated hormonal assays (FSH, LH, 17 β estradiol), pulmonary function 
tests and arterial blood gases at baseline and after 12, 24 and 36 months af-
ter initiating hormonal manipulation. Flow rates and single-breath DLCO were 
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measured according to the American Thoracic Society recommendations 
[62][63]. 
All spirometric data reported in this work are from pre-bronchodilator studies. 
Room air, resting arterial blood samples were drawn from the radial artery 
and tests were run immediately. 
The yearly rate of decline in lung function was calculated from a linear re-
gression using FEV1 and DLCO as the response variables and the time of 
each test as the independent variable, considering the first test as time zero. 
The Student’s t-test was employed to compare data sets. All reported p-
values are two-sided. All data are shown as means ± SD. 
 
RESULTS 
Of the 21 patients, sixteen had a histological proven diagnosis of LAM (13 
surgical biopsy and 3 transbronchial biopsy) and five patients exhibited clini-
cal and radiographic features consistent with LAM. Three patients were ex-
smokers, two current smokers; the remaining patients were non-smokers. 
One patient had LAM in association with Tuberous Sclerosis Complex. Of the 
21 patients, one was a male [10]. 
Estrogens suppression was obtained with oophorectomy (13 patients), trip-
torelin (6 patients), or triptorelin followed by oophorectomy (2 patients). Go-
nadal suppression was achieved in all patients. 
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Twelve patients experienced a decline in FEV1, nine patients showed im-
provement in FEV1. The mean rate of decline in FEV1 was 103mL±549mL 
after 3yrs treatment (Figure A). Indeed, we observed that the decline in FEV1 
was lower in ten of the twenty-one patients who had milder disease (initial 
FEV1>80%) than in the remaining patients (initial FEV1 <80%): 52mL vs 
158mL. It is possible that the milder disease subgroup had a more benign 
course.  
Ten patients experienced a decline in FVC, eleven patients showed im-
provement in FVC. The mean rate of improvement in FVC was 45mL±648mL 
after 3yrs treatment (Figure B). Changes in FEV1 and FVC are not statisti-
cally significant. 
DLCO test was available only for thirteen of twenty-one patients; nine of them 
had a decline in function, four showed improvement. The mean rate of de-
cline in DLCO was 2mL/min/mmHg and this value is statistically relevant 
(p=0,01). (Figure C) 
Eight patients had an improvement of PaO2 after three years of treatment; 
nine patients showed a decline in PaO2; four patients had gas exchange sta-
bility. We found that only the mean rate of improvement in PaO2 at the first 
year was statistically significant (p= 0.04). 
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DISCUSSION 
The goal of this study was to evaluate the effect of hormonal manipulation on 
lung function in patients with LAM (Table A). The mean yearly rate of decline 
in FEV1 and DLCO was lower than those observed by Johnson and Tatters-
field [64], Taveira-Da Silva et al. [65] and Harari et al. [61] (Table B).  
The PaO2 value on the third year of the study was higher than at baseline, 
but it was significantly higher only on the first year of the treatment (p=0,04). 
Harari et al. [61] instead found a significant decline in PaO2 on the third year 
such as at the first year of the study.  
It should be noted that the patients of the current report had a higher initial 
lung function than the subjects of historical controls. In our group we ob-
served a lower decline in FEV1 and DLCO, and an improvement of FVC and 
PaO2.  
It is possible that subjects with a mild disease, because of a diagnosis in an 
early stage, can have a more benign course when rapidly treated with estro-
gen suppression. 
The current study shows that the suppression of ovarian function may affect 
disease progression and it is especially true for LAM patients with a lightly–
moderate disease. So we can conclude that it’s extremely important to obtain 
an early diagnosis of LAM and to start the appropriate treatment as soon as 
possible. However because this was a retrospective study and the population 
was heterogeneous (including patients of all ages and grades of disease), our 
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findings have to be interpreted with caution. Of note, the encouraging results 
of this analysis highlight the role of the hormonal manipulation as a main stay 
in the treatment of LAM. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.A  Changes in FEV1 in twenty-one patients with LAM who were treated 
with hormonal manipulation. 
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Fig.B   Changes in FVC in twenty-one patients with LAM who were treated 
with hormonal manipulation. 
 
 
 
 
 
 
 
 
 
Fig.C   Changes in DLCO in thirteen patients with LAM who were treated with 
hormonal manipulation. 
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Table A. Pulmonary function before and during estrogen suppression in 
twenty-one patients with LAM. 
 
                                         INITIAL           1YEAR               2YEAR              3YEAR 
FEV1    (liters)                 2.38 ±0.7        2.33 ±0.8           2.28±0.87          2.28±0.9 
FVC      (liters)                 3.03±0.7         3.12±0.7            3.05±0.8            3.08±0.9 
DLCO   (mL/min/mmHg) 21.94±7.2       21.48±7.3          21.18±9.0          19.84±6.85 
PaO2   (mmHg)               84.9±14          89.0±15.5          88.7±15.6          85.2±13.9 
 
 
 
 
 
 
 
Table B. Comparison between rates of lung function decline in study subjects 
and historical control subjects 
 
Number of patients      Change FEV1/year    Change DLCO/year                    Years 
                                                  mL                    mL/min/mmHg          
 
 
32 †                                 -108±101                         -0.905±1.54                        3-3.5 
 
275  ‡                              -75±17                             -0.69±1.2                             4 
 
10  §                                -156±184                          -1.3±0.4                              1-3 
 
21   ╘                              -34±183                            -0.69± 1.08                          3 
 
 
†  From reference 64;  ‡ From reference 65; §  From reference 61; ╘   From 
the current study 
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